Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 33,561 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director owned 31,596 shares in the company, valued at $9,478,800. The trade was a 51.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 0.6%

NYSE CRL traded up $1.84 during trading hours on Thursday, hitting $296.94. The company had a trading volume of 900,812 shares, compared to its average volume of 927,534. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $303.31. The company has a market capitalization of $14.18 billion, a price-to-earnings ratio of -61.22, a P/E/G ratio of 3.08 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm’s 50 day moving average is $241.70 and its 200 day moving average is $195.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s revenue was down 2.7% compared to the same quarter last year. During the same period last year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Trending Headlines about Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Higher long-term earnings outlook: Zacks Research raised its FY2026 EPS estimate to $11.15 from $10.91, FY2027 to $12.49 from $12.11, and FY2028 to $13.82 from $13.01. The firm also increased estimates for Q2 2027 and Q3 2027, suggesting stronger expected earnings momentum beyond the current quarter. MarketBeat Charles River Laboratories stock page
• Positive Sentiment: New vaccine partnership: Medigen linked up with Charles River in an effort to take an enterovirus vaccine global. The collaboration could support future contract research and development activity, although financial details were not disclosed. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Current earnings backdrop: Charles River recently exceeded quarterly EPS and revenue expectations, reporting $3.02 in EPS and approximately $1.0 billion in revenue. However, revenue declined 2.7% year over year, and the company’s current full-year consensus EPS estimate remains $11.35. MarketBeat Charles River Laboratories stock page
• Negative Sentiment: Some near-term estimate cuts: Zacks lowered its Q3 2026 EPS estimate to $2.94 from $2.98, Q4 2026 to $3.13 from $3.15, Q1 2027 to $2.56 from $2.58, and Q4 2027 to $3.40 from $3.43. These reductions indicate some pressure on the company’s nearer-term earnings trajectory.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in Charles River Laboratories International by 22,535.2% in the second quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company’s stock worth $2,924,623,000 after purchasing an additional 12,838,761 shares during the period. Invesco Ltd. increased its stake in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares during the period. Finally, Amundi lifted its position in shares of Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after buying an additional 492,301 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on CRL. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. TD Cowen increased their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Finally, Morgan Stanley upped their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.